Crescent Biopharma filings document a clinical-stage oncology biotechnology issuer with ordinary shares listed on Nasdaq. The company’s Form 8-K reports furnish quarterly and annual financial results, business highlights, and pipeline updates involving CR-001, ADC programs, and collaboration activity.
Its SEC record also includes a definitive proxy statement covering governance, executive compensation, equity awards, shareholder voting matters, and board-related disclosures. Registration statement materials describe the company’s business, capitalization, preferred stock, warrants, convertible instruments, risk factors, and public-company structure.
Crescent Biopharma (CBIO) reported third-quarter 2026 results and clinical-program updates. Cash and cash equivalents were $289.4 million as of September 30, including $133.4 million in net proceeds from its July public offering; Crescent expects its cash to fund operations into the second half of 2028. Net loss was $37.7 million, compared with $24.6 million a year earlier.
Crescent completed dose escalation in its global Phase 1/2 ASCEND trial of CR-001, with more than 125 patients dosed, and is enrolling chemotherapy-combination expansion cohorts. Initial monotherapy data are expected in the first quarter of 2027, including preliminary response results for a first-line NSCLC cohort of up to 12 patients. The first patient has been dosed in the global Phase 1/2 APOLLO trial of CR-002, with initial data expected in the second half of 2027. Kelun-Biotech expects initial mid-2027 data from a Phase 2 study combining CR-001 with sac-TMT in NSCLC.
Crescent Biopharma, Inc. (CBIO) reported third-quarter 2026 results with $3.1 million of license-agreement revenue, versus none a year earlier. Research and development expense was $34.3 million, compared with $20.3 million, while net loss was $37.7 million versus $24.6 million. For the first nine months of 2026, revenue was $4.2 million, net loss was $85.8 million versus $61.5 million, and net cash used in operating activities was $55.3 million versus $44.8 million.
Cash and cash equivalents were $289.4 million as of September 30, 2026, compared with $213.2 million as of December 31, 2025. Management expects existing cash to fund operating plans for at least 12 months from issuance. Nine-month financing activities included $133.4 million of net proceeds from the July 2026 offering and $11.1 million net proceeds from ATM sales. The Kelun CR-001 license contributed $3.1 million in third-quarter revenue from initial drug supply. Under the SKB105 license, Crescent agreed to pay $80.0 million upfront, plus up to $345.0 million in development milestones and up to $902.5 million in sales milestones; no development milestones had been triggered as of September 30, 2026.
Crescent Biopharma, Inc. (CBIO) common stock is the subject of BlackRock, Inc.’s report of beneficial ownership of 2,075,291 shares, or 5.6% of the class, as of September 30, 2026. BlackRock reported sole voting power over 2,034,925 shares and sole dispositive power over 2,075,291 shares; shared voting and dispositive power were each zero. Various persons have rights to receive dividends or direct proceeds from sales of the shares, but no one person’s interest exceeds 5% of outstanding common shares.
Crescent Biopharma, Inc. (CBIO) reported clinical pipeline updates for CR-001 and its antibody-drug conjugate programs. In the global Phase 1/2 ASCEND trial, CR-001 monotherapy dose escalation is complete, and enrollment has begun in chemotherapy-combination expansion cohorts. Initial monotherapy data are targeted for the first quarter of 2027, including preliminary antitumor response measured by overall response rate in a first-line NSCLC cohort of up to 12 patients, and safety, tolerability, pharmacokinetic and pharmacodynamic data from more than 125 patients across multiple solid tumor types. Combination-cohort data are anticipated in mid-2027.
CR-002 received FDA allowance to proceed under an Investigational New Drug Application; its global Phase 1/2 APOLLO trial is on track to start in the fourth quarter of 2026, with initial data expected in the second half of 2027. Kelun-Biotech granted Crescent exclusive rights to research, develop and commercialize CR-003 outside Greater China; proof-of-concept data from an ongoing Phase 1/2 trial in China are expected in the first quarter of 2027. Crescent plans to initiate its first CR-001 Phase 3 trial in early 2028, pending results and further interactions with regulators.
CRESCENT BIOPHARMA, INC. (CBIO) reported that officer Ryan Lynch, its Treasurer, Senior Vice President of Finance and Chief Accounting Officer, sold 240 Ordinary Shares on September 16, 2026 at a weighted average price of $17.90 per share in an open-market or private transaction. According to the company’s disclosure, these shares were automatically sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted on December 15, 2025 and were carried out under a Rule 10b5-1 instruction adopted on February 25, 2026 solely to cover taxes related to that vesting. Following this sale, Lynch directly holds 13,631 Ordinary Shares.
CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Scientific Officer Jan Pinkas sold 658 Ordinary Shares on September 16, 2026 at a weighted average price of $17.90 per share. The shares were automatically sold to satisfy tax withholding obligations upon settlement of previously granted restricted stock units, under a Rule 10b5-1 trading instruction. Following this sale, Pinkas directly holds 21,581 Ordinary Shares.
CRESCENT BIOPHARMA, INC. (CBIO) reported that its Chief Medical Officer, Ellie Eunkyung Im, sold 623 Ordinary Shares on September 16, 2026 at a weighted average price of $17.90 per share, leaving her with 21,446 shares held directly.
According to the company’s disclosure, these shares were automatically sold to satisfy tax withholding obligations arising from the settlement of restricted stock units granted on December 15, 2025, and were effected pursuant to a Rule 10b5-1 trading instruction adopted on February 25, 2026. The price reflects multiple trades between $17.10 and $19.17 per share.
CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Financial Officer Richard William Scalzo sold 568 Ordinary Shares on September 16, 2026 in an open-market transaction at a weighted average price of $17.90 per share. The shares were automatically sold to satisfy tax withholding obligations from vesting restricted stock units under a Rule 10b5-1 trading instruction. Following this sale, he directly holds 19,730 Ordinary Shares.
CRESCENT BIOPHARMA, INC. (CBIO) reported that its General Counsel and Corporate Secretary, Barbara Harlin Bispham, sold 620 Ordinary Shares on September 16, 2026, primarily to satisfy tax withholding obligations on vesting restricted stock units. The weighted average sale price was $17.90 per share, with prices ranging from $17.10 to $19.17. After this tax-related sale, she directly holds 18,710 Ordinary Shares. The transaction was executed under a Rule 10b5-1 trading instruction adopted on February 25, 2026.
CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Executive Officer and director Joshua T. Brumm sold Ordinary Shares in two transactions, totaling 9,447 shares, on September 16 and September 18, 2026. According to the company’s disclosure, the shares were automatically sold to satisfy tax withholding obligations upon settlement of previously granted restricted stock units and were effected under a Rule 10b5-1 trading instruction adopted on February 28, 2026.